SEC For	m 4																	
	FORM	4	TES	s se			ES AND	EXCHA 0549	NGE C	OMMI	SSION		OMB	APPROV	/AL			
Section 16. Form 4 or Form 5 obligations may continue. See						A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] <u>Pietzke Steffen</u>					A	2. Issuer Name and Ticker or Trading Symbol ALX ONCOLOGY HOLDINGS INC [ALXO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				ner	
(Last)(First)(Middle)C/O ALX ONCOLOGY HOLDINGS INC.866 MALCOLM ROAD, SUITE 100					3. Date of Earliest Transaction (Month/Day/Year) 07/16/2020								VP Fin & Chief Acct Officer					
(Street) BURLINGAME CA 94107					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)													Person					
1. Title of 9	Security (Ins		ole I - Nor	1-Deriv			Curities		quired, D	4. Secur	of, or Be		5. Amou		6. Ow	nership 7	. Nature	
Date (Month/D					Day/Ye	ear) i	Execution Date f any Month/Day/Yea		Code (Ins			tr. 3, 4 and	Beneficia Owned F	lly (D) a ollowing (I) (Ir		or Indirect Instr. 4)	of Indirect Beneficial Ownership	
									Code V	Amount	(A) o (D)	Price	Price Reported Transaction (Instr. 3 and				Instr. 4)	
		-								posed of , converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, 1	1. Fransa Code (3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$19	07/16/2020			A		41,789		(1)	07/16/2030	Common Stock	41,789	\$0.00	41,78	9	D		

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on August 16, 2020.

Remarks:

<u>/s/ Peter Garcia, by power of attorney</u>

07/17/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.